MRMD's second quarter 2026 revenue reached a record $41.9 million, up 6% year-over-year and sequentially, with stable adjusted gross margins at 40%. (157)
Meramed Inc. reported Q2 2026 revenue of $41.9 million, reflecting a 6% increase both year-over-year and sequentially, surpassing analyst expectations. The company highlighted its operational discipline and product innovation amid a highly competitive cannabis market, where price compression remains a concern.
Key Takeaways
- Record revenue of $41.9 million in Q2 2026, up 6% YoY and QoQ, driven by growth in both retail and wholesale sectors.
- Adjusted EBITDA rose 10% sequentially to $3.9 million, though it declined 19% YoY from $4.8 million due to pricing pressures.
- Wholesale revenue increased 8% year-over-year, accounting for 44% of total product revenue, as market share improved across core categories.
- Retail revenue grew 7% sequentially, with notable performance in Delaware and Illinois, despite ongoing average order volume pressures.
- Adjusted gross margin remained stable at approximately 40%, a slight decline from 41.8% YoY, reflecting competitive pricing dynamics.
Record Revenue Driven by Broad-Based Growth
Meramed achieved a record consolidated revenue of $41.9 million in Q2 2026, marking a 6% increase both sequentially and year-over-year. This growth was attributed to improvements across both wholesale and retail operations, with wholesale revenue increasing 8% compared to the previous year and retail revenue up 4% year-over-year.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $41.9M | +6% | +6% |
| Adjusted EBITDA | $3.9M | -19% | +10% |
| Adjusted Gross Margin | 40% | -1.8% | -0.1% |
The company reported solid performance across various segments, significantly driven by its branded products portfolio. Management noted that their brands have outperformed the industry average in core states, indicating strong consumer demand despite an increasingly competitive environment.
Margin Stability in a Competitive Landscape
Adjusted gross margin held steady at approximately 40%, down from 41.8% in Q2 2025, yet stable compared to the previous quarter. The management attributed this stability to improved cultivation utilization and manufacturing efficiencies that offset some of the pricing pressures from increased competition, particularly in Massachusetts and Illinois.
“We believe the pricing and mix pressures we experienced this quarter are transitional and that as our newer operations mature, utilization increases and our branded products continue to gain market share, there remains a clear path to margin expansion,” said Mario Pino, CFO.
Despite the overall decline in margins experienced across the cannabis sector, Meramed's disciplined approach to capital allocation and operational improvements have positioned it to navigate these challenges effectively.
Retail Performance Highlights Growth Initiatives
Retail revenue increased 7% sequentially, with notable improvements across the Thrive Dispensary network. Management reported a 32% sequential revenue increase in Delaware, leveraging seasonal tourism patterns, and a 7% increase in Illinois, driven by enhanced loyalty programs and customer engagement strategies.
The company also highlighted a 14% increase in Thrive Perks membership since the beginning of the year, which fosters repeat business and enhances customer loyalty.
Guidance and Future Opportunities
Looking ahead, Meramed remains optimistic about its growth trajectory, particularly with the upcoming opening of its Columbus dispensary in Ohio and planned market entry into New York. Management expects these expansions to contribute positively to revenue in the latter half of 2026.
Meramed is exploring additional licensing opportunities in other states, capitalizing on its established brand strength. However, the company remains cautious about the broader market environment, particularly regarding ongoing regulatory developments in Washington that could impact the cannabis sector significantly.
Frequently Asked Questions
Did MRMD beat earnings estimates in Q2 2026?
Yes, Meramed reported Q2 2026 revenue of $41.9 million, exceeding analyst expectations. The revenue increase of 6% year-over-year and sequentially contributed to this positive outcome.
How did adjusted EBITDA perform in Q2 2026?
Adjusted EBITDA for Q2 2026 was $3.9 million, reflecting a 10% sequential increase but a 19% decline from $4.8 million in the same quarter last year due to pricing pressures in the market.
What is the company's outlook for future revenue growth?
Management expressed optimism about revenue growth, particularly with the upcoming openings of new dispensaries in Ohio and New York, which are expected to enhance revenue contributions later in the year.
How does Meramed plan to address margin pressures in the future?
Meramed plans to address margin pressures by focusing on improved cultivation utilization, enhancing operational efficiencies, and expanding its branded products portfolio, which they believe will lead to margin expansion over time.
This analysis is based on public earnings call materials and is not investment advice.
